NEW YORK, NY– Pomerantz LLP is investigating claims on behalf of investors of Recro Pharma, Inc. (“Recro” or the “Company”) (NASDAQ: REPH). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
The investigation concerns whether Recro and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On May 24, 2018, Recro announced that the U.S. Food & Drug Administration (“FDA”) had declined to approve Recro’s New Drug Application for the non-opioid pain relief treatment IV meloxicam. In its Complete Response Letter, the FDA stated that the drug’s analgesic effects did not meet FDA expectations and raised questions related to chemistry, manufacturing and controls data. On this news, Recro’s share price fell $6.79 or 54.67%, closing at $5.63 on May 24, 2018.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
Robert S. Willoughby
888-476-6529 ext. 9980
SOURCE; Pomerantz LLP, originally published on PR Newswire